GHRH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-01 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
1998 A record for the duration of life among males. The Danish-American Christian Mortensen lived 115 years and 252 days. 1998 Scientists managed to extend, in a laboratory environment, the life of normal human cells beyond the Hayflick limit using telomerase. 1999 Establishment of the Buck Institute for Research on Aging – the first institute originally established primarily to study intervention into the aging process. 1999 Sierra Sciences, a biotechnology company focused on aging research with the goal of curing human aging, was founded by William H. Andrews.
The reasons for this decline include a drop in affectionate behaviour. One team of researcher from Northwestern University who summarised the literature in 2013, identifies that this trend does not reverse throughout the marital period. Surprisingly, there has been a steady decline in the positive relationship between marriage and well-being in the United States since the 1970s. This decline is due to women reporting being less happy than previously and single men reporting being happier than previously. Research does exist, however, suggesting that compared to single people, married people have better physical and psychological health and tend to live longer. With this, a two-factor theory of love was developed by Barnes and Sternberg. This theory is composed of two components: passionate love and companionate love. Passionate love is considered to be an intense longing for a loved one. This love is often experienced through joy and sexual fulfillment, or even through rejection. On the other hand, companionate love is associated with affection, friendship and commitment. Stutzer and Frey (2006) found that the absence of loneliness and the emotional support that promotes self-esteem are both important aspects that contribute to individual well-being within marriage. Both passionate and companionate love are the foundations for every variety of love that one may experience. When passionate and companionate love are compromised in a marital relationship, satisfaction is decreased and the likelihood of divorce increases.
Brower has been credited with popularizing the term "ecological chemistry" which appeared in the title of a paper he published in Science in 1968 and again the following year in an article he wrote for Scientific American, where the term also appeared on the front cover under an image of a giant bluejay towering over two monarch butterflies. The specialized Journal of Chemical Ecology was established in 1975, and the Journal Chemoecology was founded in 1990. In 1984, the International Society of Chemical Ecology was established and in 1996, the Max Planck Institute of Chemical Ecology was founded in Jena, Germany.
Sources: en.wikipedia.org
Heseltine bought his first Jaguar, second hand and cheap because of the rise in the price of petrol owing to the Suez Crisis, for £1,750 in December 1956, upgrading to newer and more expensive models in future years. New Court Hotel was sold in 1957. At this point Heseltine went into business with another Oxford friend, Clive Labovitch, who brought out Opportunities for Graduates that year. Heseltine arranged for this to be distributed free, expanded from 40 pages to a 169-page hardback book, to final year students at all British universities, paid for by advertising. Heseltine ended his partnership with Josephs and with the aid of a £4,500 investment by Heseltine's mother (following the death of his father in 1957) he and Labovitch were able to buy a group of houses at 29–31 Tregunter Road (south of Earl's Court), adding two more in neighbouring Cathcart Road.
In compression fractures of the vertebrae, paresthesia is a complication due to the inflammation of the tissue surrounding nerves. Organs commonly affected by AS, other than the axial spine and other joints, are the heart, lungs, eyes, colon, and kidneys. Other complications are aortic regurgitation, Achilles tendinitis, AV node block, and amyloidosis. Owing to lung fibrosis, chest X-rays may show apical fibrosis, while pulmonary function testing may reveal a restrictive lung defect. Very rare complications involve neurologic conditions such as the cauda equina syndrome.
== Distribution and habitat == Psilocybe cubensis is a pan-tropical species, occurring in the Gulf Coast states and southeastern United States, Mexico, in the Central American countries of Belize, Costa Rica, Panamá, El Salvador and Guatemala, the Caribbean countries Cuba, the Dominican Republic, Puerto Rico, Guadalupe, Martinique, and Trinidad, in the South American countries of Argentina, Bolivia, Brazil, Colombia, French Guiana, Paraguay, Uruguay and Peru, Southeast Asia, including Thailand, Vietnam, Cambodia and Malaysia, India, Australia, Fiji, and possibly Nepal and Hawaii. Psilocybe cubensis is found on cow (and occasionally horse) dung, sugar cane mulch or rich pasture soil, with mushrooms appearing from February to December in the northern hemisphere, and November to April in the southern hemisphere. In Asia, the species grows on water buffalo dung. Along with other fungi that grow on cow dung, P. cubensis is thought to have colonized Australia with the introduction of cattle there, 1800 of which were on the Australian mainland by 1803—having been transported there from the Cape of Good Hope, Kolkata and the American west coast. In Australia, the species grows between northern Queensland to southern New South Wales. In March 2018, several Psilocybe cubensis specimens were collected in Zimbabwe in the Wedza District of Mashonaland East province, approx. 120 km southeast of Harare. This was the first reported occurrence of a psilocybin mushroom in Zimbabwe.
Sources: en.wikipedia.org
== Works == Tew has co-authored 2 books focusing on carcinogenesis and cancer treatment strategies. He co-wrote Preclinical and Clinical Modulation of Anticancer Drugs with Peter J. Houghton and Janet A. Houghton, providing an analysis of theoretical and practical approaches to the design and implementation of modulation principles. His collaborative work with Gary D. Kruh, Basic Science of Cancer, explored the advancements in cancer research, covering interrelated topics such as tumor suppressor genes, apoptosis, transcriptional regulation, pharmacology of anticancer drugs, cytogenetic techniques, oncogenes, and signal transductions. Tew co-edited books from the series Advances in Cancer Research alongside Paul B. Fisher, where they provided reviews on diverse cancer research topics. In a review published in the Journal of Medicinal Chemistry, Thomas J. Bardos wrote about the series, "This rapidly growing series of volumes containing many excellent, highly informative, in-depth reviews on a variety of timely topics relating to cancer research has always been most representative in the areas of tumor biology and immunology."
==== Dopamine ==== In certain brain regions, amphetamine increases the concentration of dopamine in the synaptic cleft by modulating DAT through several overlapping processes. Amphetamine can enter the presynaptic neuron either through DAT or, to a lesser extent, by diffusing across the neuronal membrane directly. As a consequence of DAT uptake, amphetamine produces competitive reuptake inhibition at the transporter. Upon entering the presynaptic neuron, amphetamine provokes the release of Ca2+ from endoplasmic reticulum stores, an effect that raises intracellular calcium to levels sufficient for downstream kinase-dependent signalling. In parallel, amphetamine also increases intracellular cAMPTooltip cyclic adenosine monophosphate, which activates protein kinase A (PKA) and protein kinase C (PKC), whilst elevated intracellular Ca2+ activates PKC alone. Phosphorylation of DAT by either kinase induces transporter internalization (non-competitive reuptake inhibition), but PKC-mediated phosphorylation alone induces the reversal of dopamine transport through DAT (i.e., dopamine efflux). TAAR1 has been identified as a biomolecular target of amphetamine that initiates some of amphetamine's kinase-dependent signaling cascades. When TAAR1 signals via Gs-coupled receptors, intracellular cAMP increases through adenylyl cyclase activation and activates PKA and PKC, in turn phosphorylating DAT.
Leslie Hicks is an American full professor of analytical chemistry at the University of North Carolina at Chapel Hill. Her work primarily focuses on the study of proteomics and protein post-translational modifications using mass spectrometry, and identifying biologically active peptides in plants.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.